AGENTIX Discusses 2022 Clinical Development Efforts and Potential Uplisting with The Stock Day Podcast

from Stock Day Media · host Stock Day Media

The Stock Day Podcast welcomed AGENTIX (AGTX)(“the Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of metabolic diseases including type 2 diabetes mellitus, chronic obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). CEO of the Company, Rudy Mazzocchi, joined Stock Day host Everett Jolly. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Episode metadata supplied by the publisher feed · Published Jan 4, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

AGENTIX Discusses 2022 Clinical Development Efforts and Potential Uplisting with The Stock Day Podcast

0:00 11:40

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Wild WinsDay Wild WinsDay Pump the hump with WILD WINSday 🐪💪: Your 3-minute weekly video boost for leadership, sales, marketing, and business breakthroughs to WIN the day!

Frequently Asked Questions

How long is this episode of Stock Day Media?

This episode is 11 minutes long.

When was this Stock Day Media episode published?

This episode was published on January 4, 2022.

Can I download this Stock Day Media episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!